Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapy for Muscle-Invasive Bladder Cancer

  • Genitourinary Cancers (W Oh and M Galsky, Section Editors)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion Statement

In the last 25 years, there has been an improved understanding of the pathogenesis of muscle-invasive bladder cancer (BC). Development of new treatment strategies has followed. We have progressed from the awareness of the efficacy of platinum compounds, especially cisplatin, as single agents to the development of effective drug combinations with greater attention in improving safety profiles while impacting on survival. Peri-operative chemotherapy (CHT) is the standard of care for non-metastatic disease. The most evidence in terms of a survival advantage is derived from neoadjuvant chemotherapy (NC) trials, but adjuvant medical treatment should be strongly considered when NC has not been utilized. Patient selection and a multidisciplinary approach are essential. Platinum-based CHT is still the standard of care for both early and advanced disease. A deeper knowledge of the pathogenesis of BC will derive from gene expression profiling (GEP), and this will give us new prognostic and predictive tools to develop more targeted treatments. A high mutational rate has been observed in BC, which can generate neoantigens that initiate cancer immunity. Immunotherapy will become a pivotal treatment for BC, in the very near future. Emerging data are encouraging, and these treatments may well revolutionize the medical approach to this disease while CHT will play a less important role.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2014. Available from: http://globocan.iarc.fr. Accessed Aug 29th 2015.

  2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2015. CA Cancer J Clin. 2015;65:5–29.

    Article  PubMed  Google Scholar 

  3. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27:289–93.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Chavan S, Bray F, Lortet-Tieulent J, Goodman M, Jemal A. International variations in bladder cancer incidence and mortality. Eur Urol. 2014;66(1):59–73.

    Article  PubMed  Google Scholar 

  5. James AC, Gore JL. The costs of non-muscle invasive bladder cancer. Urol Clin N Am. 2013;40(2):261–9.

    Article  Google Scholar 

  6. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World health organization classification of tumors. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC press; 2004.

    Google Scholar 

  7. American Cancer Society. Bladder Cancer; Early Detection, Diagnosis, and Staging Topics. http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-survival-rates.

  8. Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63(1):45–57.

    Article  PubMed  Google Scholar 

  9. Hautmann RE, Gschwend JE, de Petriconi RC, Kron M, Volkmer BG. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol. 2006;176(2):486–92. discussion 491–2.

    Article  PubMed  Google Scholar 

  10. Zaid HB, Patel SG, Stimson CJ, Resnick MJ, Cookson MS, Barocas DA, et al. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology. 2014;83(1):75–80.

    Article  PubMed  Google Scholar 

  11. International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171–7.

    Article  PubMed Central  Google Scholar 

  12. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66.

    Article  PubMed  CAS  Google Scholar 

  13. Wallace DM, Raghavan D, Kelly KA, Sandeman TF, Conn IG, Teriana N, et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol. 1991;67:608–15.

    Article  PubMed  CAS  Google Scholar 

  14. Coppin CM et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1996;14(11):2901–7.

    PubMed  CAS  Google Scholar 

  15. Martinez Pineiro JA, Gonzalez Martin M, Arocena F. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: prospective randomized phase III study. J Urol. 1995;153:964–73.

    Article  PubMed  CAS  Google Scholar 

  16. Abol-Enein H, El Makresh M, El Baz M, Ghoneim M. Neo-adjuvant chemotherapy in treatment of invasive transitional bladder cancer: a controlled, prospective randomised study. Br J Urol. 1997;80 suppl 2:49.

    Google Scholar 

  17. Bassi P, Pappagallo GL, Sperandio P, Monfardini S, Pagano F, Cosciani S. Neoadjuvant M-VAC chemotherapy for invasive bladder cancer: results of a multicenter phase III trial. J Urol (Suppl). 1999;161:264. abstract 1021.

    Article  Google Scholar 

  18. GISTV (Italian Bladder Cancer Study Group). Neoadjuvant treatment for locally advanced bladder cancer: a randomized prospective clinical trial. J Chemother. 1996;8:345–6.

    Google Scholar 

  19. Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellsten S, Hannisdal E. Five year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol. 1996;155:1903–6.

    Article  PubMed  CAS  Google Scholar 

  20. Sherif A, Rintala E, Mestad O, Nilsson J, Holmberg L, Nilsson S, et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer—Nordic cystectomy trial 2. Scand J Urol Nephrol. 2002;36:419–25.

    Article  PubMed  CAS  Google Scholar 

  21. Sherif A, Holmberg L, Rintala E, Mestad O, Nilsson J, Nilsson S, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic Studies. Eur Urol. 2004;45:297–303.

    Article  PubMed  CAS  Google Scholar 

  22. Parmar MK. Neoadjuvant chemotherapy in invasive bladder cancer. Trial Design Prog Clin Biol Res. 1990;353:1115–8.

    Google Scholar 

  23. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48(2):202–5.

    Article  Google Scholar 

  24. Di Trapani E, Sanchez Salas R, Gandaglia G, Rocchini L, Moschini M, Lizee D, et al. A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum‑based chemotherapy. World J Urol. 2015. doi:10.1007/s00345-015-1640-2

  25. Gandhi NM, Baras A, Munari E, Faraj S, Reis LO, Liu JJ, et al. Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. Urol Oncol. 2015;33(5):204.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  26. Baras AS, Gandhi N, Munari E, Faraj S, Shultz L, Marchionni L, et al. Identification and validation of protein biomarkers of response to neoadjuvant platinum chemotherapy in muscle invasive urothelial carcinoma. PLoS One. 2015;10(7), e0131245.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A. On behalf of the ESMO Guidelines Working Group. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii40–8.

    Article  PubMed  Google Scholar 

  28. NCCN clinical practice guideline in Oncology (NCCN guidelines). Bladder cancer. Version 2.2015.NCCN.org.

  29. Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015;121(15):2586–93.

    Article  PubMed  CAS  Google Scholar 

  30. Plimack ER, Hoffman-Censits JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014;32:1895–901.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  31. Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014;32(18):1889–94.

    Article  PubMed  CAS  Google Scholar 

  32. https://clinicaltrials.gov/ct2/show/NCT01812369

  33. Logothetis CJ, Johnson DE, Chong C, Dexeus FH, Sella A, Ogden S, et al. Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer:an update. J Clin Oncol. 1988;6:1590–6.

    PubMed  CAS  Google Scholar 

  34. Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991;145:459–67.

    PubMed  CAS  Google Scholar 

  35. Stockle M, Meyenburg W, Wellek S, Voges G, Gertenbach U, Thuroff JW, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 nad pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy results of a controlled prospective study. J Urol. 1992;148:302–7.

    PubMed  CAS  Google Scholar 

  36. Stockle M, Meyenburg W, Wellek S. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long term results of a controlled prospective study and further clinical experience. J Urol. 1995;153:47–52.

    Article  PubMed  CAS  Google Scholar 

  37. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cosplatin, vinblastine and methotrexate chemotherapy for muscle-invasive bladder cancer. J Urol. 1996;155:495–9.

    Article  PubMed  CAS  Google Scholar 

  38. Studer UE, Bacchi M, Biedermann C, Jaeger P, Kraft R, Mazzucchelli L, et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol. 1994;152:81–4.

    PubMed  CAS  Google Scholar 

  39. Bono AV, Benvenuti C, Reali L, Pozzi E, Gibba A, Cosciani-Cunico S, et al. Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group. Prog Clin Biol Res. 1989;303:533–40.

    PubMed  CAS  Google Scholar 

  40. Sylvester R, Sternberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: What we do not know and why. Ann Oncol. 2000;11(7):851–6.

    Article  PubMed  CAS  Google Scholar 

  41. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48:189–99. discussion 199–201.

    Article  Google Scholar 

  42. Cognetti F, Ruggeri EM, Felici A, et al. Adjuvant chemotherapy with cisplatin + gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy. An Italian multicenter randomised phase III trial. Ann Oncol. 2012;23(3):695–700.

    Article  PubMed  CAS  Google Scholar 

  43. Paz-Ares L, Solsona E, Esteban E, Saenz A, Gonzalez-Larriba JL, Antón A, et al. on behalf of the SOGUG and GUO-AEU groups Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the SOGUG (Spanish Oncology Genito-Urinary Group) 99/01 study. J Clin Oncol. 2010. ASCO Annual Meeting Abstracts. Vol 28, No 18_suppl (June 20 Supplement), 2010: LBA4518.

  44. Leow JJ, Martin-Doyle W, Rajagopal PS, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014;66:42–54. Meta-analysis of reference of randomized trials about adjuvant CHT; it assesses the real efficacy of post-operative treatments.

    Article  PubMed  CAS  Google Scholar 

  45. Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015;16(1):76–86. The last large randomized trial comparing deferred CHT at progression vs post-operative treatment.

    Article  PubMed  Google Scholar 

  46. Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol. 2005;174(1):14–20.

    Article  PubMed  CAS  Google Scholar 

  47. Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, et al. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer. 2013;119(16):3012–9.

    Article  PubMed  CAS  Google Scholar 

  48. Yagoda A. Chemotherapy of urothelial tract tumors. Cancer. 1987;60:574–85.

    Article  PubMed  CAS  Google Scholar 

  49. Loehrer P, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group Study. J Clin Oncol. 1992;10:1066–73.

    PubMed  Google Scholar 

  50. Logothetis CJ, Dexeus F, Finn L, et al. A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastastic urothelial tumors. J Clin Oncol. 1990;8:1050–5.

    PubMed  CAS  Google Scholar 

  51. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77.

    PubMed  Google Scholar 

  52. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–8.

    Article  PubMed  Google Scholar 

  53. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17(10):3173–81.

    PubMed  CAS  Google Scholar 

  54. Sternberg CN, de Mulder PH, Schornagel JH, Théodore C, Fossa SD, van Oosterom AT, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001;19(10):2638–46.

    PubMed  CAS  Google Scholar 

  55. Bellmunt J, Guillem V, Paz-Ares L, et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium: Spanish Oncology Genitourinary Group. J Clin Oncol. 2000;18:3247–55.

    PubMed  CAS  Google Scholar 

  56. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30:1107–13.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  57. Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with every-2-week gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001;92(12):2993–8.

  58. Guardino AE, Srinivas S. Gemcitabine and paclitaxel as second line chemotherapy for advanced urothelial malignancies [abstract]. Proc Am Soc Clin Oncol. 2002;21. Abstract 2413.

  59. Fechner G, Siener R, Reimann M, Kobalz L, Albers P, German Association of Urologic Oncology (AUO) Bladder Cancer Study Group. Randomised phase II trial of gemcitabine, paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract. 2006;60:27–31.

    Article  PubMed  CAS  Google Scholar 

  60. Kaufman DS, Carducci MA, Kuzel TM, et al. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol. 2004;22:393–7.

    Article  PubMed  CAS  Google Scholar 

  61. Meluch AA, Greco FA, Burris HA, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2001;19:3018–24.

    PubMed  CAS  Google Scholar 

  62. Li J, Juliar B, Yiannoutsos C, et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol. 2005;23:1185–91.

    Article  PubMed  CAS  Google Scholar 

  63. Calabrò F, Lorusso V, Rosati G, Manzione L, et al. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer. 2009;115(12):2652–9.

    Article  PubMed  Google Scholar 

  64. Shannon C et al. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium. Effective treatment of patients with poor prognostic features. Ann Oncol. 2001;12:947–52.

    Article  PubMed  CAS  Google Scholar 

  65. Petrioli et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. Cancer. 1996;77(2):344–51.

    Article  PubMed  CAS  Google Scholar 

  66. Bellmunt J et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer. 1997;80:1966–72.

    Article  PubMed  CAS  Google Scholar 

  67. Carteni G, Dogliotti L, Crucitta E, et al. Phase II randomised trial of gemcitabine plus cisplatin (GP) and gemcitabine plus carboplatin (GC) in patients (pts) with advanced or metastatic transitional cell carcinoma of the urothelium (TCCU). Proc ASCO. 2003;22:384. Abstr 1543.

    Google Scholar 

  68. De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30(2):191–9.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28:1850–5.

    Article  PubMed  Google Scholar 

  70. Bellmunt J, Théodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454–61.

  71. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152–65. whole genome mRNA expression profiling identifying three different molecular cathegories of BC with different prognosis.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  72. McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, et al. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol. 2015. Identification of predictive value of molecular categories of BC in patients treated with Neoadjuvant CHT. It needs further validation.

  73. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–22. Comprehensive evaluation of molecular alterations in BC. It could be useful to find targets for future treatments.

    Article  Google Scholar 

  74. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  75. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression of B7-H1 (PDL1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother. 2007;56:1173–82.

    Article  PubMed  CAS  Google Scholar 

  76. Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007;109:1499–505.

    Article  PubMed  CAS  Google Scholar 

  77. Petrylak DP, et al. A phase Ia study of ATEZOLIZUMAB (anti-PDL1): updated response and survival data in urothelial bladder cancer (UBC), Abstract number: #8030, ASCO 2015.

  78. Rosenberg J, et al. Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): results from a pivotal multicenter phase II study (IMvigor 210). Abstract number 21LBA, ECC 2015.

  79. clinicaltrials.gov: NCT02450331

  80. clinicaltrials.gov: NCT02302807

  81. Plimack ER, Gupta S, Bellmunt J, et al. A phase Ib study of pembrolizumab in patients with advanced urothelial tract cancer. Presented at: ESMO 2014 Congress; September 26–30, 2014; Madrid, Spain. LBA23A.

  82. clinicaltrials.gov: NCT02256436

  83. clinicaltrials.gov: NCT01928394

  84. clinicaltrials.gov: NCT02387996

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, San Camillo Forlanini Hospital, Padiglione Flajani, Circonvallazione Gianicolense 87, Rome, 00152, Italy

    Patrizia Trenta MD, Fabio Calabrò MD, Linda Cerbone MD & Cora N. Sternberg MD, FACP

Authors
  1. Patrizia Trenta MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fabio Calabrò MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Linda Cerbone MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cora N. Sternberg MD, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrizia Trenta MD.

Ethics declarations

Conflict of Interest

Patrizia Trenta, Fabio Calabrò, Linda Cerbone, and Cora N. Sternberg declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Genitourinary Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Trenta, P., Calabrò, F., Cerbone, L. et al. Chemotherapy for Muscle-Invasive Bladder Cancer. Curr. Treat. Options in Oncol. 17, 6 (2016). https://doi.org/10.1007/s11864-015-0376-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-015-0376-y

Keywords

Search

Navigation